Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Andrew Hill¹, Anna Garratt², Jacob Levi³, Jonathan Falconer⁴, Leah Ellis⁵, Kaitlyn McCann⁵, Victoria Pilkington⁶, Ambar Qavi⁵, Junzheng Wang⁵, Hannah Wentzel⁵

¹. Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, L7 3NY, UK
². Department of Infectious Diseases, University Hospital of Wales, Cardiff and Vale University Health Board, UK
³. Department of Intensive Care, University College London Hospital, ULCH NHS Trust, London, UK
⁴. Department of Infectious Diseases, Chelsea and Westminster Hospital, Imperial NHS Trust, London, UK
⁵. Faculty of Medicine, Imperial College London, UK
⁶. Oxford University Clinical Academic Graduate School, University of Oxford, UK

Corresponding author:

Dr Andrew Hill PhD
Department of Pharmacology and Therapeutics
University of Liverpool,
70 Pembroke Place
Liverpool L69 3GF, UK
Email: microhaart@aol.com
Abstract

Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-CoV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality (Relative Risk 0.44 [95%CI 0.25-0.77]; p=0.004; 35/1064 (3%) deaths on ivermectin; 93/1063 (9%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and a wide range of doses were evaluated. Currently, WHO recommends the use of ivermectin only inside clinical trials. A network of large clinical trials is in progress to validate the results seen to date.

Keywords: SARS-CoV2, COVID-19, Ivermectin, Repurposed
Introduction

The SARS-CoV-2 pandemic continues to grow, with over 350,000 new infections and over 7,000 deaths recorded worldwide daily in May 2021 [1]. Protective vaccines have been developed, but current supplies are too low to cover worldwide demand in the coming months [2]. Researchers worldwide are urgently looking for interventions to prevent new infections, or prevent disease progression, and lessen disease severity for those already infected.

While research on new therapeutic agents for COVID-19 is key, there is also great interest in evaluating the potential of already existing medicines against COVID-19, and many clinical trials are in progress to ‘re-purpose’ drugs normally indicated for other diseases. The known safety profiles, shortened development timelines, and well-established markets (with low price points and higher capacity to deliver at scale) for most of the already existing compounds proposed for COVID-19 are particularly advantageous compared to new drug discovery in a pandemic situation. Three re-purposed anti-inflammatory drugs have shown significant survival benefits to date: the corticosteroid dexamethasone in the UK RECOVERY trial [3], and the Interleukin-6 (IL-6) receptor antagonist drugs, tocilizumab and sarilumab, in the REMAP-CAP trial and RECOVERY trial [4,5]. Other re-purposed antimicrobials such as, hydroxychloroquine, lopinavir/ritonavir, remdesivir and interferon-beta, have shown no significant survival benefit in two large, randomized trials [3, 6] despite initial reports of efficacy, underscoring the need for caution when interpreting early clinical trial data.

Dexamethasone is recommended for use by the WHO and has proven survival benefits for oxygen-dependent patients with COVID-19, while tocilizumab and sarilumab improve survival for patients in intensive care [3, 4]. Preliminary data suggest that nitazoxanide and budesonide may have a role in mild infection [7,8]. However, there are no approved treatments for patients with mild SARS-CoV-2 infection, either to prevent disease progression or reduce viral transmission. Treatments increasing viral clearance rate may reduce the risk of onward transmission but this requires empirical demonstration.
Ivermectin is a well-established anti-parasitic drug used worldwide for a broad number of parasites and also for topical use against rosacea. Antiviral activity of ivermectin has been demonstrated recently for SARS-CoV-2 in Vero/hSLAM cells [9]. However, concentrations required to inhibit viral replication in-vitro ($EC_{50} = 2.2 - 2.8 \mu M$; $EC_{90} = 4.4 \mu M$) are not achieved systemically after oral administration of the drug to humans [9, 10].

The drug is estimated to accumulate in lung tissues (2.67 times that of plasma) [11], but this is also unlikely to be sufficient to maintain target concentrations for pulmonary antiviral activity [10, 12]. Notwithstanding, ivermectin is usually present as a mixture of two agents and although mainly excreted unchanged in humans, has two major metabolites [13]. Current data are insufficient to determine whether the minor form or a circulating metabolite has higher direct potency against SARS-CoV-2, but it seems likely that it would need to be profoundly more potent than the reported values.

Ivermectin has also demonstrated immunomodulatory and anti-inflammatory mechanisms of action in preclinical models of several other indications. In-vitro studies have demonstrated that ivermectin suppresses production of the inflammatory mediators nitric oxide and prostaglandin E2 [14]. Furthermore, avermectin (from which ivermectin is derived) significantly impairs pro-inflammatory cytokine secretion (IL-1β and TNF-α) and increases secretion of the immunoregulatory cytokine IL-10 [15]. Ivermectin also reduced TNF-α, IL-1, and IL-6, and improved survival in mice given a lethal dose of lipopolysaccharide [16]. Preclinical evidence to support these immunomodulatory and anti-inflammatory mechanisms of action have also been generated in murine models [17, 18]. Finally, in Syrian golden hamsters infected with SARS-CoV-2, subcutaneous ivermectin demonstrated a reduction in the IL-6/IL-10 ratio in lung tissues. In this study, ivermectin also prevented pathological deterioration [19]. Ultimately, various potential mechanisms of action for ivermectin against COVID19 exist and are undergoing further investigation, as recently summarised in a review article [20].

At standard doses, of 0.2-0.4mg/kg for 1-2 days, ivermectin has a good safety profile and has been distributed to billions of patients worldwide in mass drug administration programs. A recent meta-analysis found no significant difference in adverse events in those given...
higher doses of ivermectin, of up to 2mg/kg, and those receiving longer courses, of up to 4 days, compared to those receiving standard doses [21]. Ivermectin is not licensed for pregnant or breast-feeding women, or children <15kg. The WHO Guidelines Group found that in 16 RCTs with 2407 participants ivermectin improved mortality outcomes compared with control but rated the quality of available evidence as low or very low [22]. Currently, the WHO does not recommend the use of ivermectin outside clinical trials.

The objective of this systematic review and meta-analysis was to combine available results from new published or unpublished randomized trials of ivermectin in SARS-CoV-2 infection to inform current guidelines.

Methods

The systematic review and meta-analysis was conducted according to PRISMA guidelines. A systematic search of PUBMED and EMBASE was conducted to identify randomized control trials (RCTs) evaluating treatment with ivermectin for SARS-CoV-2 infected patients. Clinical trials with no control arm, or those evaluating prevention of infection were excluded alongside non-randomized trials and case-control studies. Key data extracted included baseline characteristics (age, sex, weight, oxygen saturation, stage of infection), changes in inflammatory markers, viral suppression after treatment, clinical recovery, hospitalization and survival. Data were extracted and cross-checked by two independent reviewers (HW and LE).

Search strategy and selection criteria

RCTs were eligible for inclusion if they compared an ivermectin-based regimen with a comparator or standard of care (SOC) for the treatment of SARS-CoV-2 infection. PRISMA checklist, PRISMA flow diagram, the search terms, and inclusion/exclusion criteria used are detailed in Supplementary Figure 1, Supplementary Tables 1, 2 and 3.

Registry databases were searched up until the 12th of May 2021. Clinicaltrials.gov [23] was searched using key words COVID, SARS-CoV-2 and ivermectin to identify studies. The WHO International Clinical Trials Registry Platform (ICTRP) was accessed via the COVID-NMA Initiative’s mapping tool [24] and Stanford University’s Coronavirus Antiviral Research
Database (CoV-RDB) [25] to identify additional trials listed on other national, and international registries. Literature searches via PubMed, Embase, and the preprint servers MedRxiv and Researchsquare were conducted to identify published studies. Duplicate registrations, non-randomised studies and prevention studies were excluded following discussion between the authors.

Additionally, the research teams conducting unpublished clinical trials were contacted and requested to join regular international team meetings from December 2020 to May 2021. All results available from eligible unpublished studies were also included in this systematic review.

All of the clinical trials included in this meta-analysis were approved by local ethics committees and all patients gave informed consent.

The primary outcome was all-cause mortality from randomization to the end of follow-up. Secondary outcomes included time to viral clearance, PCR negativity at day 7, clinical recovery, time to clinical recovery, mechanical ventilation, duration of hospitalization and number of hospitalizations. Changes in inflammatory markers, viral suppression, clinical recovery and hospitalization were also summarized for individual trials where endpoints could not be combined.

**Data analysis**

Statistical analyses for all-cause mortality, time to viral clearance and clinical recovery were conducted using published data summaries. For the mortality outcome, clinical trials with at least one death reported were included in this analysis. Furthermore, any hospitalization within 12 hours of randomization was excluded. Treatment effects were expressed as risk ratios (RR) for binary outcomes and mean difference (MD) for continuous outcomes. For each outcome, we pooled the individual trial statistics using the random-effects inverse-variance model; a continuity correction of 0.5 was applied to treatment arms with no deaths. Heterogeneity was evaluated by $I^2$. The significance threshold was set at 5% (two-sided) and all analyses were conducted using Revman 5.3. A funnel plot for the mortality outcome was
created to assess publication bias and small study effects; the p-value was estimated from the regression-based Harbord test for small study effects.

All studies included in this analysis were assessed for risk of bias using the Cochrane Collaboration risk of bias standardized assessment tool [26]. The outcome of this assessment is given in Supplementary Table 3. Each study was assessed for risk of bias for the primary endpoint, viral load, and survival outcomes. The primary endpoint in the trials tended to be clinical recovery which is more subjective and likely to be influenced by knowledge of treatment arms. An assessment was also carried out on more objective endpoints including survival and viral load which are less likely to be influenced by this bias. Where information was not available in published papers, clinical trial investigators were proactively contacted to inform the risk bias analysis.

Results

24 RCTs involving a total of 3328 participants were included in this meta-analysis. The sample sizes of each trial ranged from 24 to 400 participants. Of the 24 included studies, eight were published papers, nine were available as pre-prints, six were unpublished results shared for this analysis, and one reported results via a trial registry website.

Overall, nine trials investigated ivermectin as a single dose (Table 1A) [27-35], 15 trials investigated multi-day dosing up to seven days (Table 1B) [36-50], of which four trials were dose-ranging [28,39, 46, 48]. In the included trials, ivermectin was largely investigated in mild/moderate participants (15 trials). Overall, 18 trials were either single or double-blinded and six were open-label.

Evaluation of Studies.

An evaluation of the quality of the studies included in this meta-analysis was conducted according to the Cochrane Collaboration tool to assess the risk of bias across the following outcomes: primary endpoints, viral load, and survival. For the primary outcome assessment, 6/24 (25%) studies were assessed as high risk of bias [Supplementary table 3A]. However, in assessments of more objective outcomes, including viral load and mortality, the number of
high risk studies was lower. In the PCR assessment, 3/15 (20%) of the studies were assessed as high risk [Supplementary Table 3B]. In the survival assessment, 1/11 (9%) of the studies were assessed as high risk of. [Supplementary Table 3C].

**Effects on Inflammatory Markers**

Five trials provided results of the effect of ivermectin on inflammatory markers including C-reactive protein (CRP), ferritin and d-dimer (Table 2). Four of these trials demonstrated significant reductions in CRP compared to control. Furthermore, in the Elgazzar trial [36], ivermectin significantly reduced ferritin levels compared to control in the severe patient population while no significant difference was demonstrated in the mild/moderate population. The Okumus trial [47] showed significantly greater reductions in ferritin on day 10 of follow-up for ivermectin versus control. The Chaccour [35] and Ahmed [46] trials showed no significant difference in ferritin count between ivermectin and control. Elgazzar [36] showed significant differences in d-dimer between ivermectin and control in both the mild/moderate and severe populations. Okumus [47] showed significant differences in d-dimer on day 5 whilst Chaccour [35] found no significant differences in d-dimer between ivermectin and control, but with a smaller sample size.

**Effects on Viral Clearance**

Three different endpoints were used to analyze viral clearance: the percentage of patients undetectable on a set day (Table 3A), the number of days from randomization to negativity (Table 3B), and other measures such as cycle time (Ct) values and dose-response correlations (Table 3C). The Kirti [43] and Okumus [47] trials included viral load analysis only in a subset of patients. The effects of ivermectin on viral clearance were generally smaller when dosed on only one day. Several studies showed no statistically significant effect of ivermectin on viral clearance [28, 29, 34].

The three studies randomizing patients to different doses or durations of ivermectin showed apparent dose-dependent effects on viral clearance. First, in the Babalola trial (n=60) [48], the 0.4mg/kg dose showed trends for faster viral clearance than the 0.2mg/kg dose. Second, in the Mohan trial (n=125) [28], the 0.4 mg/kg dose of ivermectin led to a numerically higher
percentage of patients with viral clearance by day five than the 0.2mg/kg dose. Third, in the Ahmed trial (n=72) [46], ivermectin treatment for five days led to a higher percentage of patients with viral clearance at day 13 compared with one day of treatment. Finally, in Krolewiecki (n=45) [50], PK/PD correlations showed significantly faster viral clearance for patients with PK exposures above 160ng/mL.

The effect of ivermectin on viral clearance was most pronounced in the randomized trials evaluating doses of up to five days of ivermectin using doses of 0.4mg/kg. At these doses, there were statistically significant effects on viral clearance in all four randomized trials. In a meta-analysis of viral clearance with subgroups of dose duration, there were significant differences in time to viral clearance in favour of ivermectin (Mean Difference -3.00 days [95%CI -4.96, -1.03]; p=0.003, Figure 1A). In a sensitivity analysis excluding high risk of bias studies, similar effects of ivermectin on time to viral clearance were seen [Supplementary Figure 2]. Furthermore, in another analysis, ivermectin showed improved viral clearance at day 7 (Relative Risk  1.35 [95%CI 1.05-1.75]; p=0.02, Figure 1B).

Effects on Clinical Recovery and Duration of Hospitalization

Definitions of clinical recovery varied across trials, as shown in Table 4. In Table 4A, three of the six trials showed significantly faster time to clinical recovery on ivermectin compared to control. In four trials, ivermectin showed significantly shorter duration of hospitalization compared to control (Table 4B).

In a meta-analysis of clinical recovery with subgroups of dose duration, there were significant differences in time to clinical recovery in favour of ivermectin (Mean Difference -1.58 days [95%CI -2.80, -0.35]; p=0.01, Figure 1C). Additionally, ivermectin showed a 29% improvement in clinical recovery in an analysis with subgroups of dose duration (RR 1.29 [95%CI 1.12-1.47]; p=0.0003, Figure 1D).

Ivermectin demonstrated a shorter duration of hospitalization compared to control (Mean Difference -4.27 days [95%CI -8.60-0.06]; p=0.05, Figure 1E). Ivermectin was not associated with a lower risk of hospitalization compared to control (RR 0.40 [95%CI 0.14-1.08]; p=0.07, Figure 1F). However, this analysis involved only four trials in 704 participants. In a sensitivity
analysis including any hospitalization within 12 hours of randomization, there were significantly fewer hospitalisations compared to control (RR 0.32 [95%CI 0.13-0.80]; p=0.01, Supplementary Figure 3).

**Effects on Survival**

11 randomized trials reported that at least one person had died post-randomization and were included in the analysis (Table 5). Across these 11 trials in 2127 patients, there were 35/1064 (3%) deaths in the ivermectin arms, versus 93/1063 (9%) deaths in the control arms. In a combined analysis using inverse variance weighting, ivermectin showed a 56% reduction in mortality (RR 0.44 [95%CI 0.25-0.77]; p=0.004, Figure 1G). Heterogeneity was moderate, $I^2 = 43\%$. There was a 70% improvement in survival in the subgroup of mild/moderate participants (RR 0.30 [95%CI 0.15-0.58]; p=0.0004). The total number of deaths was small, the analysis was based on 128 deaths and there was no significant difference between ivermectin and control in the severe subgroup (0.58 [95%CI 0.25-1.32]; p=0.19).

Consistent results were observed in an analysis excluding high risk of bias studies (RR 0.45 [95%CI 0.24-0.82]; p=0.01, Supplementary Figure 4). When only low risk of bias studies were included this result was also maintained (RR 0.31 [95%CI 0.10-0.90]; p=0.03, Supplementary Figure 5).

Additional subgroup analysis of the mortality outcome with trials separated by dose-duration, blinding and control group showed consistent survival benefit and no significant subgroup differences were found (Supplementary Figures 6, 7 and 8).

A leave-one-out sensitivity analysis was performed and no single study had a substantial effect on the overall effect size (Supplementary Table 4).

A funnel plot for the mortality outcome showed no significant effects of publication bias: the treatment effects were similar in studies of different sizes, p= 0.618 (Supplementary Figure 9).
Ivermectin was not associated with lower risk of mechanical ventilation (RR 0.97 [95%CI 0.57-1.67]; p=0.92, Figure 1H]. However, this estimate was based on five studies in 641 participants including only 49 events.

Discussion

This systematic review and meta-analysis of 24 RCTs (n = 3328) showed ivermectin treatment reduces inflammatory markers, achieves viral clearance more quickly and improves survival compared with SOC. The effects of ivermectin on viral clearance were stronger for higher doses and longer durations of treatment. These effects were seen across a wide range of RCTs conducted in several different countries.

The results from this analysis have emerged from the International Ivermectin Project Team meetings between December 2020 and May 2021. Independent research teams were conducting the trials across 16 countries and agreed to share their data, which was often unpublished, to accelerate the speed of reporting and to ensure their fragmented research, widespread across the world, could contribute to global learning. Viral clearance was evaluated by Polymerase Chain Reaction (PCR) assays in all the studies. We have only included randomized clinical trials in this meta-analysis. The 24 RCTs included were designed and conducted independently, with results combined in May 2021. However each individual trial was small and a wide range of population types included. Clinical recovery definitions differed between trials and there were no significant differences on survival in severe participants.

Secondary Endpoints

Secondary endpoints for some RCTs included biomarkers of disease severity. Some of these provide evidence for an anti-inflammatory mechanism of action of ivermectin in SARS-CoV-2 infected patients. Previous meta-analyses have demonstrated that high levels of CRP, ferritin, d-dimer and lymphocytopenia are related to COVID-19 severity and hyper-inflammation [51, 52]. Studies of IL-6 receptor antagonists have been shown to reduce CRP and d-dimer levels in patients with COVID-19 [5].
Ivermectin may also have a role in short-term prevention of SARS-CoV-2 infection, suggested by pilot studies [53, 54]. This potential benefit also needs to be validated in larger randomized trials.

**Mechanism of action**

At the time of writing, knowledge gaps prevent a robust conclusion about the mechanism of action of ivermectin. Ivermectin’s broad-spectrum anti-viral effects have been proposed to be related to its impact on the NF-κB pathway and via binding to the host cell importin α/β1 heterodimer, nuclear transport proteins responsible for nuclear entry of cargoes, and these effects in turn also prevent viral replication.

As discussed in the introduction, the current *in-vitro* EC$_{50}$ estimates (2.2µ, 2.4µM and 2.8µM depending on gene assay analyzed by RT-qPCR) are still 35 times higher than plasma concentrations following normal oral dosing. Even doses 8.5x fold the FDA recommended 200µg/kg of 1.7mg/kg only reach plasma concentrations of 0.28µM [55]. The increased bioavailability in the fed state and higher concentrations seen in lung tissue compared to plasma is still below the current published EC$_{50}$ results.

However, EC$_{50}$ results can vary greatly depending on lab methodology; cell lineage, viral quantification methods, the strain of the virus cultured and the Multiplicity of infection used. This is an established phenomenon: viral polymorphisms of influenza demonstrated a 5-fold variation in EC$_{50}$ of different neuraminidase assays that looked at the susceptibility of field isolates of influenza virus against oseltamivir [56]. Specifically in SARS-CoV-2, EC$_{50}$s for previously repurposed drugs have varied significantly. Remdesivir, now licensed for SARS-CoV-2, performed >10 fold better in hACE2 augmented A549 cells (0.115 µM) than Vero E6 (1.28µM) [57]. whereas other examples of repurposed drugs like sofosbuvir demonstrated over 10-fold variation in EC$_{50}$ when used in Vero E6 cells versus HUH7 [58]. Consequently, the EC$_{50}$ so far demonstrated for ivermectin against SARS-CoV-2 should be interpreted with caution as it is unlikely to be one set value and liable to change depending on the lab
methodology used. In vitro assays for ivermectin should be repeated for different cell types using different measures of activity.

Limitations

A key limitation to this meta-analysis is the comparability of the data, with studies differing in dosage, treatment duration, and inclusion criteria. Furthermore, the standard of care used in the control arm differed between trials. In this meta-analysis, trials that used active controls such as hydroxychloroquine or lopinavir/ritonavir were combined together with those that used placebo or standard care. However, lopinavir/ritonavir and hydroxychloroquine have shown no overall benefit or harm in large randomized trials and meta-analyses. [7, 59-61] Furthermore, additional analyses in this paper separating trials by subgroups of standard care/placebo and active control showed no significant difference between groups.

Another limitation is that ivermectin was given in combination with doxycycline in three trials. Individual trials may not have power to detect treatment effects on rare endpoints such as survival. Outcome measures were not standardized; viral clearance was measured in most trials, but at different time points and with different PCR cycle thresholds. The reliability of PCR tests for quantification purposes has been the subject of substantive debate. Most studies were conducted in populations with only mild/moderate infection and some trials excluded patients with multiple comorbidities.

For open label studies, there is a risk of bias in the evaluation of subjective endpoints such as clinical recovery and hospital discharge. However, the risk is lower for objective endpoints such as viral clearance and survival. We have attempted to control for publication bias by contacting each research team conducting the trials directly. This has generated more results than would be apparent from a survey of published clinical trials only but means that many of the included trials have not been peer-reviewed. Review and publication of RCTs generally takes three to six months. It has become common practice for clinical trials of key COVID-19 treatments to be evaluated from preprints, such as for the WHO SOLIDARITY, RECOVERY and REMAP-CAP trials [4,5,7].
These RCTs have been conducted in a wide range of countries, often in low-resource conditions and overburdened healthcare systems. Larger RCTs are currently underway in Spain, South America, Africa and North America, with results from an additional 5000 participants expected in Summer 2021 (Supplementary Table 5).

Despite limitations, this analysis suggests a dose and duration-dependent impact of ivermectin on rate of viral clearance. These trials evaluated a wide range of ivermectin dosing, from 0.2mg/kg for 1 day to 0.6mg/kg for 5 days. This wide range of doses allowed an estimation of dose-dependency on viral clearance but reduces the number of patients included that were consistently administered the same dose for the same duration. The maximum effective dose of ivermectin is not yet clear and new clinical trials are evaluating higher doses, up to 1.2mg/kg for 5 days.

The 56% survival benefit seen in this meta-analysis is based on 128 deaths, in 11 different clinical trials. This is a smaller total number of deaths than the RECOVERY trial, which led to the approval of dexamethasone and is based on 1592 deaths. However, the observed survival benefit of 56% in ivermectin is stronger than for other repurposed drugs, requiring a smaller sample size to be demonstrated. Emerging mortality results from larger studies of ivermectin will require careful evaluation and may change the conclusions from the current analysis.

Several other repurposed medications have shown promise in early smaller trials for example sofosbuvir/daclatasvir, colchicine and remdesivir but the benefit was not seen later in larger trials. This meta-analysis of 24 RCTs in 3328 patients showed a 56% improvement in survival, faster time to clinical recovery and signs of a dose-dependent effect of viral clearance for patients given ivermectin versus control treatment. This benefit needs to be validated in larger confirmatory trials.
Acknowledgements

We would like to thank all the clinical staff, the research teams and the patients who participated in these studies.

Funding: Rainwater foundation

Potential Conflicts of Interest: None of the authors has declared a conflict of interest.

Patient Consent Statement: All of the clinical trials included in this meta-analysis were approved by local ethics committees and all patients signed informed consent.
References

1. WHO. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2020 [cited 2021 March 9]. Available from: https://covid19.who.int/

2. Stolberg SG, LaFraniere S. Warning of Shortages, Researchers Look to Stretch Vaccine Supply. New York Times [Internet]. 2020; Available from: https://www.nytimes.com/2021/01/05/us/politics/coronavirus-vaccine-supply.html

3. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. New England Journal of Medicine. 2020. DOI: 10.1056/NEJMoa2021436

4. The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report. medRxiv [preprint] 2020; Available at: https://doi.org/10.1101/2021.01.07.21249390

5. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England). 2021 May 1;397(10285):1637–45.

6. WHO Solidarity Trial Consortium. 2021. “Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.” The New England Journal of Medicine 384 (6): 497–511. https://doi.org/10.1056/NEJMo2023184.

7. Mahase E. Covid-19: Budesonide shortens recovery time in patients not admitted to hospital, study finds BMJ 2021; 373:n957 doi:10.1136/bmj.n957

8. Romark. ROMARK ANNOUNCES INITIAL RESULTS OF PHASE 3 CLINICAL TRIAL OF NT-300 TABLETS FOR THE TREATMENT OF COVID-19 [Internet]. 2020 [cited 2021 Apr 22]. Available from: https://www.romark.com/romark-announces-initial-results-of-phase-3-clinical-trial-of-nt-300-tablets-for-the-treatment-of-covid-19/

9. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787.

10. Arshad U, Pertinez H, Box H, et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909.

11. Schmith, V., Zhou, J. Lohmer, 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clinical Pharmacology & Therapeutics, 108(4), pp.762-765.
12. Jermain B, Hanafin PO, Cao Y, Lifschitz A, Lanusse C, Rao GG. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. J Pharm Sci. 2020;109(12):3574-3578. doi:10.1016/j.xphs.2020.08.024

13. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans--a mini-review. AAPS J. 2008;10(1):42-46. doi:10.1208/s12248-007-9000-9

14. Zhang X, Song Y, Xiong H, et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol. 2009 Mar;9(3):354-9. doi: 10.1016/j.intimp.2008.12.016.

15. Ci X, Li H, Yu Q, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009 Aug;23(4):449-55. doi: 10.1111/j.1472-8206.2009.00684.x.

16. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008 Nov;57(11):524-9. doi: 10.1007/s00011-008-8007-8

17. Ventre E, Rozières A, Lenief V, et al. Topical ivermectin improves allergic skin inflammation. Allergy. 2017 Aug;72(8):1212-1221. doi: 10.1111/all.13118.

18. Yan S, Ci X, Chen N, Chen C, et al. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res. 2011 Jun;60(6):589-96. doi: 10.1007/s00011-011-0307-8.

19. de Melo GD, Lazarini F, Larrous F, et al. Anti-COVID-19 efficacy of ivermectin in the golden hamster. bioRxiv 2020.11.21.392639; doi: https://doi.org/10.1101/2020.11.21.392639

20. Navarro, M., Camprubi, D., Requena-Méndez, A., et al. 2020. Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 75(4), pp.827-834.

21. Zaidi AK, Dehgan-Mobaraki P. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. The Journal of Antibiotics. 2021 Jun 15;1:3.

22. WHO. Therapeutics and COVID-19: living guideline [Internet]. 2020. [cited 2021 Apr 22]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1

23. NIH ClinicalTrials.gov. [Accessed 14th December]

24. Thu Van Nguyen, Gabriel Ferrand, Sarah Cohen-Boulakia, Ruben Martinez, Philipp Kapp, Emmanuel Coquery, for the COVID-NMA consortium. (2020). RCT studies on preventive measures and treatments for COVID-19 [Data set]. Zenodo. http://doi.org/10.5281/zenodo.4266528
25. Tzou PL, Tao K, Nouhin J, et al. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses. 2020;12(9):1006. Published 2020 Sep 9. doi:10.3390/v12091006

26. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.

27. Mahmud et al. ClinicalTrials.gov. National Library of Medicine. NCT04523831. Clinical trial of ivermectin plus doxycycline for the treatment of confirmed COVID-19 infection. Available at: https://clinicaltrials.gov/ct2/show/study/NCT04523831 [Accessed 15/12/2020]

28. Mohan A, Tiwari P, Suri T et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. Research Square. 2021. https://doi.org/10.21203/rs.3.rs-191648/v1 [preprint]

29. Chowdhury et al. A randomised trial of Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients. 2020 [Internet] Available at: https://doi.org/10.21203/rs.3.rs-38896/v1

30. Gonzalez et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. medRxiv. Available at: https://www.medrxiv.org/content/10.1101/2021.02.18.21252037v1. [preprint]

31. Raad et al. 2020. In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial. 2020 Available at: http://www.chictr.org.cn/showproj.aspx?proj=54707 [unpublished]

32. Bukhari, Asghar, Perveen et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease. medRxiv. 2020. https://doi.org/10.1101/2021.02.02.21250840 [preprint]

33. Rezai et al. Effect of Ivermectin on COVID-19: A multicenter double-blind randomized clinical trial. 2020. Available at: https://en.irct.ir/trial/49174 [unpublished]

34. Podder S, Chowdhury N, Sina M, Ul Haque W. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study. IMC J Med Sci 2020; 14 (2): 002

35. Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021 Jan 19:100720.

36. Elgazzar A, Hany B, Youssef S, Hafez M, Moussa H, Eltaweel A. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. [Pre-print]. 28th December 2020. Research Square. https://www.researchsquare.com/article/rs-100956/v3
37. López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. Published online March 04, 2021. doi:10.1001/jama.2021.3071

38. Chahla R, Ruiz L, Mena T et al. Cluster Randomised Trials - Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers. Researchsquare. 2021. Available at: https://doi.org/10.21203/rs.3.rs-495945/v1 [preprint]

39. Niaee M, Gheibi N, Namdar P, et al. Invermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized, multi-center clinical trial. [Preprint]. 24th November 2020. Research Square. Available at: https://doi.org/10.21203/rs.3.rs-109670/v1

40. Galan et al (2021) Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathogens and Global Health, DOI: 10.1080/20477724.2021.1890887

41. Abd-Elsalam et al. Ivermectin as a Novel Therapy for COVID-19 Treatments. Available at: https://clinicaltrials.gov/ct2/show/NCT04403555 [unpublished]

42. Hashim H, Maulood M, Rasheed A, Fatak D, Kabah K, Abdulamir A. Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. [Preprint]. 27th October 2020. medRxiv. Available at: https://doi.org/10.1101/2020.10.26.20219345

43. Kirti R, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial. [Preprint]. 9th January 2021. Medrxiv. doi: https://doi.org/10.1101/2021.01.05.21249310

44. Petkov S. Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (covid-19) and manifested clinical symptoms. 2021. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002091-12/BG (accessed January 2021) [unpublished]

45. Schwartz E. Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate covid-19. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04429711 [unpublished]

46. Ahmed S, Karim M, Ross A, et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2020 Dec 2:S1201-9712(20)32506-6. doi: 10.1016/j.ijid.2020.11.191.

47. Okumuş, N., Demirtürk, N., Çetinkaya, R.A. et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis 21, 411 (2021). https://doi.org/10.1186/s12879-021-06104-9

48. O E Babalola, C O Bode, A A Ajayi, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in
49. Chachar A, Khan K, Asif M, Khaqan A, Basri R. Effectiveness of ivermectin in SARS-CoV-2 / COVID-19 patients. International Journal of Sciences 09(2020):31-35 DOI: 10.18483/ijSci.2378

50. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial. [Preprint]. 11th November 2020. SSRN. Available at: http://dx.doi.org/10.2139/ssrn.3714649

51. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-1028. https://doi.org/10.1515/cclm-2020-0369

52. Singh K, Mittal S, Gollapudi S, Butzmann A, Kumar J, Ohgami RS. A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. International journal of laboratory hematology. 2020 Oct 3.

53. Clinicaltrials.gov. NCT04701710. Prophylaxis Covid-19 In Healthcare Agents By Intensive Treatment With Ivermectin And Iota-Carrageenan. Available at: https://clinicaltrials.gov/ct2/show/NCT0470171019 [Accessed 12/01/2021].

54. Clinicaltrials.gov. NCT04422561. Prophylactic Ivermectin In COVID-19 Contacts - Study Results. Available at: https://clinicaltrials.gov/ct2/show/results/NCT04422561. [Accessed 12/01/2021].

55. Wang K, Gao W, Dou Q, et al. Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer. Autophagy. 2016 Dec;12(12):2498-2499. doi: 10.1080/15548627.2016.1231494.

56. Abed Y, Baz M, Boivin G. et al. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral therapy. 2006 Jan 1;11(8):971.

57. Shi PY, Xie X, Muruato et al. Nanoluminescence SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. bioRxiv. 2020 Jan 1. https://www.biorxiv.org/content/biorxiv/early/2020/06/23/2020.06.22.165712.full.pdf

58. 54. Levi et al Interpreting in-vitro data for sofosbuvir against SARS-CoV-2: cell lineage is key. Oral abstract. ISIRV conference. 6-8 October 2020.

59. Ghazy R, Almaghraby A, Shaaban R, Kamal A, Beshir H, Moursi A et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with
azithromycin in COVID-19 treatment. Scientific Reports [Internet]. 2020;10(1). Available from: https://www.nature.com/articles/s41598-020-77748-x

60. Alhumaid, Saad, Abbas Al Mutair, Zainab Al Alawi, Naif Alhmeed, Abdul Rehman Zia Zaidi, and Mansour Tobaqi, 2020. “Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.” Tropical Medicine and Infectious Disease 5 (4). https://doi.org/10.3390/tropicalmed5040180.

61. RECOVERY Collaborative Group. 2020. “Lopinavir-Ritonavir in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial.” Lancet (London, England) 396 (10259): 1345–52. https://doi.org/10.1016/S0140-6736(20)32013-4.

62. Mills et al. Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: “The Hope Coalition - 1”. ClinicalTrials.gov [Internet]. 2020. https://www.clinicaltrials.gov/ct2/show/NCT04403100?term=NCT04403100&draw=2&rank=1

63. DNDi. ANTICOV Clinical Trial. 2020 [Internet] Available at: https://dndi.org/research-development/portfolio/anticov/

64. Rezai et al. Double-blind placebo-controlled clinical trial of evaluating the effectiveness of Ivermectin in treatment of outpatients with COVID-19 in 2021. IRCT [Internet]. 2020. https://www.irct.ir/trial/53949

65. Rezai et al. Double-blind placebo-controlled clinical trial of evaluating the effectiveness of Ivermectin in treatment of admitted with COVID-19 in 2021. IRCT [Internet]. 2020. Available at: https://www.irct.ir/trial/54402

66. Munoz et al. Multicenter, phase III, double-blind, randomized, parallel, placebo-controlled trial to evaluate the efficacy and safety of an early administration of Ivermectin for three consecutive days to prevent hospitalization related to SARS-Cov-2 (COVID-19) in adults over 50 years old with less than 5 days of symptoms. Exeltis [personal communication]

67. Mukonzo et al. Safety and Efficacy of low dose aspirin/ ivermectin combination therapy for treatment of covid-19 patients (IVCOM). Clinicaltrials.gov [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT04768179?cond=COVID-19&intr=ivermectin&spfd_s=01%2F02%2F2021&spfd_e=12%2F03%2F2021&draw=2

68. Avila et al Efficacy of ivermectin in outpatients with non-severe Covid-19. Clinicaltrials.gov [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT04834115?term=ivermectin&draw=2
List of Tables and figures

Table 1: Trial Summaries

A: Ivermectin trials with Dosing on day 1 only

B: Ivermectin trials with multi-day dosing

Table 2: Changes in Inflammatory Markers

Table 3: Effects of ivermectin on viral clearance

A: Effects of ivermectin on viral clearance (binary)

B: Effects of ivermectin on time to viral clearance

C: Effects of ivermectin on other measures of viral clearance

Table 4: Effects of ivermectin on clinical recovery and hospitalization

A: Time to clinical recovery

B: Effects of ivermectin on duration of hospitalization

C: Number of Participants with clinical recovery by Day 7 to 10 post-randomization

Table 5: Effects of ivermectin on survival
**Figure 1A**: Forest plot of time to viral clearance by dose-duration.

**Figure 1B**: Forest plot of PCR negativity at day 7 *Kirti et al and Schwartz et al measured at day 6

**Figure 1C**: Forest plot of time to clinical recovery by dose-duration.

**Figure 1D**: Forest plot of clinical recovery (binary) by dose duration

**Figure 1E**: Forest plot of duration of hospitalization by dose

**Figure 1F**: Forest plot of new hospitalizations in trials on outpatients

**Figure 1G**: Forest plot of survival by severity

**Figure 1H**: Forest plot of mechanical ventilation
Table 1: Trial Summaries

Table 1A: Ivermectin trials with Dosing on day 1 only

| Study          | Country     | Sample Size | Daily dose | Duration | Patients     | Ivermectin Arm                | Comparator Arm                |
|----------------|-------------|-------------|------------|----------|--------------|-------------------------------|-------------------------------|
| Mahmud et al [25]† | Bangladesh  | 363         | 12 mg      | 1 day (DB) | Mild/ moderate | Ivermectin + Doxycycline + SOC | SOC                           |
| Mohan et al [26]† | India       | 125         | 0.2-0.4 mg/kg (elixir) | 1 day (DB) | Mild / moderate | Ivermectin + SOC | Placebo + SOC |
| Chowdhury [27]† | Bangladesh  | 116         | 0.2 mg/kg  | 1 day (DB) | PCR positive  | Ivermectin + Doxycycline      | HCQ + Azithromycin            |
| Gonzalez [28]†  | Mexico      | 106         | 12 mg      | 1 day (DB) | Severe       | Ivermectin                   | Placebo                       |
| Raad et al [29]† | Lebanon     | 100         | 0.2 mg/kg  | 1 day (SB) | Mild         | Ivermectin + SOC | SOC                           |
| Study            | Country     | Sample Size | Dose (mg/kg) | Treatment Duration | Severe Degree | Treatment Group(s)       |
|------------------|-------------|-------------|--------------|--------------------|---------------|--------------------------|
| Asghar et al     | Pakistan    | 86          | 0.2          | 1 day (OL)         | Mild / moderate | Ivermectin + SOC          |
| Rezai et al      | Iran        | 69          | 0.2          | 1 day (DB)         | Moderate / severe | Ivermectin + SOC          |
| Podder et al     | Bangladesh  | 62          | 0.2          | 1 day (OL)         | Mild          | Ivermectin + SOC          |
| SAINT            | Spain       | 24          | 0.4          | 1 day (DB)         | Moderate      | Ivermectin               |

SOC = Standard of care; OL = open label; SB = single-blind; DB = double-blind
| Study               | Country   | Sample Size | Daily dose | Duration       | Patients       | Ivermectin Arm | Comparator Arm |
|---------------------|-----------|-------------|------------|----------------|----------------|----------------|----------------|
| Elgazzar et al [36] | Egypt     | 400         | 0.4 mg/kg  | 5 days (DB)    | Mild to severe | Ivermectin + SOC | HCQ + SOC      |
| Lopez-Medina et al [37] | Colombia   | 398         | 0.3 mg/kg  | 5 days (DB)    | Mild           | Ivermectin     | Placebo        |
| Chahla et al [38]   | Argentina  | 254         | 24mg       | 1 / week for 4 weeks (OL) | Mild | Ivermectin + SOC | SOC            |
| Niaee et al [39]    | Iran      | 180         | 0.2 - 0.4 mg/kg | 1-3 days (DB) | Mild / moderate | Ivermectin + SOC | SOC + Placebo  |
| Fonseca et al [40]  | Brazil     | 168         | 14mg       | 3 days (DB)    | Severe         | Ivermectin     | Hydroxychloroquine or Chloroquine |
| Abd-Elsalam et al [41] | Egypt     | 164         | 12 mg      | 3 days (OL)    | PCR Positive   | Ivermectin +SOC | SOC            |
| Hashim et al [42]   | Iraq      | 140         | 0.2 mg/kg  | 2-3 days (SB)  | Symptomatic    | Ivermectin + Doxycycline + SOC | SOC            |
| Study                        | Country   | Sample Size | Treatment | Route | Study Days | Disease Severity | Treatment Group 1 | Control Group      |
|------------------------------|-----------|-------------|-----------|-------|------------|------------------|-------------------|-------------------|
| Kirti et al [43] *           | India     | 112         | 12 mg     | 2 days (DB) | Mild / moderate | Ivermectin + SOC | SOC + Placebo     |
| Petkov et al [44] *          | Bulgaria  | 100         | 0.4 mg/kg | 3 days (DB) | Mild / moderate | Ivermectin       | Placebo           |
| Schwartz et al [45] †        | Israel    | 94          | 12 - 15 mg | 3 days (DB) | Mild / moderate | Ivermectin       | Placebo           |
| Ahmed et al [46] *           | Bangladesh| 72          | 0.2 mg/kg | 5 days (DB) | Mild        | Ivermectin + SOC | SOC + Placebo     |
| Okumus et al [47] †          | Turkey    | 60          | 0.2 mg/kg | 5 days (DB) | Severe      | Ivermectin + SOC | FAVI/HQ/AZI (SOC) |
| Babalola et al [48] *        | Nigeria   | 60          | 0.1 - 0.2 mg/kg | 2 / week (DB) | Mild        | Ivermectin + SOC | Placebo + LPV/r (SOC) |
| Chachar et al [49] †         | Pakistan  | 50          | 0.2 mg/kg | 2 days (OL) | Mild        | Ivermectin + SOC | SOC               |
| Krolewiecki et al [50] †     | Argentina | 45          | 0.6 mg/kg | 5 days (OL) | Mild to moderate | Ivermectin + SOC | SOC               |

* Denoted studies were evaluated as having fair or good overall quality of evidence using the Cochrane Risk of Bias Tool. See Supplementary Table 3 for further details.

† Denoted studies were evaluated as having limited overall quality of evidence using the Cochrane Risk of Bias Tool. See Supplementary Table 3 for further details.

SOC = Standard of care
Table 2: Changes in inflammatory Markers

|                        | CRP (mg/L) | Ferritin (μg/L) | D-dimer (mg/L) |
|------------------------|------------|-----------------|----------------|
|                        | Ivermectin | Control | p value | Ivermectin | Control | p value | Ivermectin | Control | p value |
| **Elgazzar, Egypt**    |            |         |         |            |         |         |            |         |         |
| (n=200, mild/moderate COVID-19) |            |         |         |            |         |         |            |         |         |
| Baseline               | 48.4       | 50.6    |         | 168        | 172     |         | 4.8        | 5.4      |         |
| Day 7                  | 8.3        | 4.8     | p<0.001 | 95         | 98      | 0.62    | 0.5        | 0.7      | p<0.001 |
| **Elgazzar, Egypt**    |            |         |         |            |         |         |            |         |         |
| (n=200, severe COVID-19) |            |         |         |            |         |         |            |         |         |
| Baseline               | 64.8       | 68.2    |         | 420        | 334     |         | 8.2        | 8.6      |         |
| Day 7                  | 28.6       | 58.6    | p<0.001 | 104        | 294     | p<0.001 | 0.7        | 1.9      | p<0.001 |
| **Okumus, Turkey**    |            |         |         |            |         |         |            |         |         |
| (n=60)                 |            |         |         |            |         |         |            |         |         |
| Baseline               | 340.3      | 215.0   |         | 683        | 747     |         | 1.3        | 1.3      |         |
| Day 5                  | 51.8       | 194.3   | p<0.01  | 875        | 1028    | 0.12    | 5.9        | 3.6      | 0.22    |
| Day 10                 | 36.1       | 92.4    | p<0.05  | 495        | 1207    | p<0.01  | 0.7        | 1.5      | p<0.05  |
| **Chaccour, Spain**   |            |         |         |            |         |         |            |         |         |
| (n=24)*                |            |         |         |            |         |         |            |         |         |
|                | Baseline | 3.5 | 3.0 | 165 | 156 | 0.3 | 0.3 |
|----------------|----------|-----|-----|------|------|-----|-----|
| Day 7          | 1.0      | 1.1 | n.s** | 125 | 199 | n.s** | 0.3 | 0.3 |
| Day 14         | 0.8      | 0.6 | n.s** | 152 | 145 | n.s** | 0.3 | 0.3 |

Ahmed, Bangladesh (n=45, Ivermectin 5 days)

|                | Baseline | 22.0 | 29.0 | 269 | 222 | -   | -   |
|----------------|----------|------|------|-----|-----|-----|-----|
| Day 7          | 3.0      | 14.0 | p<0.05+ | 211 | 218 | 0.06+ | -   | -   |

Ahmed, Bangladesh (n=46, Ivermectin 1 day)

|                | Baseline | 26.0 | 29.0 | 259 | 222 | -   | -   |
|----------------|----------|------|------|-----|-----|-----|-----|
| Day 7          | 11.0     | 14.0 | 0.07+ | 213 | 218 | 0.17+ | -   | -   |

Iran Niaee (n=60, Ivermectin- 0.2 mg)*

|                | Baseline | 200.0 | 270.0 | - | - | - | - |
|----------------|----------|------|------|---|---|---|---|
| Day 5          | 85.0     | 245.0 | p<0.001++ | - | - | - | - |

Iran Niaee (n=60, Ivermectin- 0.2, 0.2, 0.2 mg)*

|                | Baseline | 390.0 | 270.0 | - | - | - | - |
|----------------|----------|------|------|---|---|---|---|
| Day 5          | 200.0    | 245.0 | p<0.001++ | - | - | - | - |

Iran Niaee (n=60, Ivermectin- 0.4 mg)*

|                | Baseline | 250.0 | 270.0 | - | - | - | - |
| Day 5 | 80.0 | 245.0 | p<0.001++ | -   | -   | -   | -   |
|-------|------|-------|-----------|-----|-----|-----|-----|
| Iran Niaee (n=60, Ivermectin- 0.4, 0.2, 0.2 mg)* |       |       |           |     |     |     |     |
| Baseline | 340.0 | 270.0 | -         | -   | -   | -   | -   |
| Day 5   | 170.0 | 245.0 | p<0.001++ | -   | -   | -   | -   |

*Median presented, all other data mean.

** ‘n.s.’ was used when no statistically significant difference was found, but the actual p-value was not reported by the individual authors and could not be calculated by current authors.

+p value compares within group changes from baseline to end point of ivermectin group. ++p value shows significance of total changes from baseline. All other p values compare ivermectin vs. control.

Normal ranges: CRP(<10mg/L), Ferritin(11-336μg/L) D-dimer(<0.5mg/L).
Table 3: Effects of ivermectin on viral clearance

Table 3A:

| Study      | Country (n) | Daily dose | Duration | Viral load endpoint | Result | P value |
|------------|-------------|------------|----------|---------------------|--------|---------|
|            |             |            |          | IVM vs Control      |        |         |
| **Number Detectable or Undetectable (%)** |             |            |          |                     |        |         |
| Mahmud et al | Bangladesh,  | 12 mg      | 1 day (DB) | Undetectable       | 92% vs 80% | p < 0.001 |
|             | n=363       |            |          |                     | Day 14          |         |
| Asghar et al | Pakistan,   | 0.2 mg/kg  | 1 day    | Undetectable       | 90% vs 44%  | p < 0.001 |
|             | n=86        |            |          |                     | Day 7         |         |
| Mohan et al | India,      | 0.2mg/kg Elixir | 1 day  | Undetectable       | 35% vs 31%  | p = 0.3  |
|             | n=125       |            |          |                     | Day 5        |         |
| Mohan et al | India,      | 0.4mg/kg Elixir | 1 day  | Undetectable       | 48% vs 31%  | p = 0.3  |
|             | n=125       |            |          |                     | Day 5        |         |
| Kirti et al | India,      | 12 mg      | 2 days   | Undetectable       | 24% vs. 32% | p = 0.35 |
|             | n=112       |            |          |                     | Day 6        |         |
| Study          | Location | Dose (mg/kg) | Duration (Days) | End Point | Success | Comparison | p-value |
|---------------|----------|--------------|-----------------|-----------|---------|------------|---------|
| Podder et al  | Bangladesh, n=62 | 0.2 | 1 (OL) | Day 10 PCR neg | 90% vs 95% | > 0.05 |
| Okumus et al  | Turkey, n=60 | 0.2 | 5 (DB) | Day 10 PCR Neg | 88% vs 38% | 0.01 |
| Schwartz et al | Israel n=100 | 12-15 | 3 (DB) | Day 10 PCR Neg Ct>30 | 81% vs 60% | 0.02 |
### Table 3B: Effects of Ivermectin on Time to Viral Clearance

| Study          | Country (n)     | Daily dose | Duration | Viral load endpoint | Result          | P value  |
|----------------|-----------------|------------|----------|---------------------|-----------------|----------|
| **Time to Viral Clearance (Days)** |                 |            |          |                     | IVM vs Control |         |
| Chowdhury      | Bangladesh, n=112 | 0.2 mg/kg  | 1 day (DB) | Time to PCR neg     | 9 vs 9.3 days   | p = 0.23 |
| Elgazzar et al | Mild/Moderate, n=200 | 0.4 mg/kg  | 5 days (OL) | Days detectable     | 5 vs 10 days    | p < 0.001|
| Elgazzar et al | Severe, n=200    | 0.4 mg/kg  | 5 days (OL) | Days detectable     | 6 vs 12 days    | p < 0.001|
| Babaloa et al  | Nigeria, n=60    | 0.1 mg/kg  | 2 / week (DB) | Time to PCR neg | 6 vs 9 days    | p = 0.003|
| Babaloa et al  | Nigeria, n=60    | 0.2 mg/kg  | 2 / week (DB) | Time to PCR neg | 4.7 vs 9 days  | p = 0.003|
| Study                  | Location     | Dose (mg/kg) | Days (DB) | End Point                  | Time to PCR neg | p     |
|-----------------------|--------------|--------------|-----------|---------------------------|----------------|-------|
| Ahmed et al *         | Bangladesh, n=72 | 0.2          | 5         | Time to PCR neg           | 10 vs 13 days  | 0.02  |
| Ahmed et al *         | Bangladesh, n=72 | 0.2          | 1         | Time to PCR neg           | 11.5 vs 13 days | 0.27  |
| Petkov et al          | Bulgaria, n=100  | 0.4          | 3         | Time to PCR neg           | 4.52 vs 5.06   | 0.341 |
Table 3C: Effect of ivermectin on other measures of viral clearance.

| Study            | Country (n)       | Daily dose | Duration | Viral load endpoint | Result         | P value |
|------------------|-------------------|------------|----------|---------------------|----------------|---------|
| Other Measures of Viral clearance                      |                   |            |           |                     |                |         |
| Raad et al       | Lebanon, n=100    | 0.2 mg/kg  | 1 day    | Day 3              | Ct values      | p = 0.01 |
|                  |                   |            |          |                     | 30.1 ± 6.22    | vs. 18.96 ± 3.26 |
| Krolewiecki et al* | Argentina, n=45  | 0.6 mg/kg  | 5 days   | PK/PD              | Dose-related   | p = 0.02 |

*Dose-response effect seen
### Table 4: Effects of ivermectin on clinical recovery and hospitalization

#### Table 4A: Time to clinical recovery

| Study            | Country | Daily dose | Duration | Endpoint                  | Results              | P value |
|------------------|---------|------------|----------|---------------------------|----------------------|---------|
| Mohan et al      | India   | 0.2 mg/kg  | 1 day (SB) | Time to clinical recovery | 4.8 vs 4.6 days      | p = 0.77 |
|                  | n=125   | Elixir     |          |                           |                      |         |
| Mohan et al      | India   | 0.4 mg/kg  | 1 day (SB) | Time to clinical recovery | 4.3 vs 4.6 days      | p = 0.77 |
|                  | n=125   | Elixir     |          |                           |                      |         |
| Hashim et al     | Iraq    | 0.2 mg/kg  | 2-3 days (SB) | Time to clinical recovery | 10.6 vs 17.9 days  | p < 0.001 |
|                  | n=140   |            |          |                           |                      |         |
| Chowdhury et al  | Bangladesh | 0.2 mg/kg | 1 day (DB) | Time to clinical recovery | 5.9 vs 6.9 days      | p = 0.071 |
|                  | n=116   |            |          |                           |                      |         |
| Study            | Location  | Dose     | Course (route) | Effect Measure     | Comparison                          | p-value |
|------------------|-----------|----------|----------------|--------------------|-------------------------------------|---------|
| Podder et al     | Bangladesh| 0.2 mg/kg| 1 day (OL)     | Time to clinical   | 5.3 vs 6.3 days                     | p > 0.05|
| Rezai et al      | Iran      | 0.2 mg/kg| 1 days (OL)    | Time to clinical   | 4.1 vs 5.2 days                     | p = 0.018|
| Lopez-Medina et al | Colombia | 0.3 mg/kg| 5 days (DB)    | Time to clinical   | 10 vs 12 days                       | p=0.53  |
Table 4B: Effect of Ivermectin on duration of hospitalization

| Study            | Country       | Daily dose | Duration | Endpoint         | Results     | P value  |
|------------------|---------------|------------|----------|------------------|-------------|----------|
| Rezai et al      | Iran          | 0.2 mg/kg  | 1 days (OL) | Days in hospital | 6.9 vs 8.4 days | p = 0.01 |
|                  | n=69          |            |          |                  |             |          |
| Raad et al       | Lebanon       | 0.2 mg/kg  | 1 day (OL) | Hospitalization  | 0% vs 6%    | p = 0.00 |
|                  | n=100         |            |          |                  |             |          |
| Niaee et al      | Iran          | 0.2 - 0.4 mg/kg | 1-3 days (DB) | Days in hospital | 6.5 vs 7.5 days | p = 0.006 |
|                  | n=165         |            |          |                  |             |          |
| Elgazzar et al   | Egypt         | 0.4 mg/kg  | 5 days (OL) | Days in hospital | 5 vs 15 days | p < 0.001 |
| Mild/moderate    | n=200         |            |          |                  |             |          |
| Elgazzar et al   | Egypt         | 0.4 mg/kg  | 5 days (OL) | Days in hospital | 6 vs 18 days | p < 0.001 |

**Duration of hospitalization**

**Studies:** Rezai et al, Raad et al, Niaee et al, Elgazzar et al
| Study            | Location         | Dose        | Duration (DB) | Outcome: Days in Hospital | p-value |
|------------------|------------------|-------------|---------------|---------------------------|---------|
| Severe n=200     |                  |             |               |                           |         |
| Ahmed et al      | Bangladesh, n=72 | 0.2 mg/kg   | 5 days (DB)   | 9.6 vs 9.7                | 0.93    |
| Ahmed et al      | Bangladesh, n=72 | 0.2 mg/kg   | 1 day (DB)    | 10.1 vs 9.7               | 0.93    |
| Abd El-Salam et al | Egypt n=164   | 12 mg       | 3 days        | 8.82 vs. 10.97            | 0.09    |
| Gonzalez et al   | Mexico n=106    | 12 mg       | 1 day         | 6 vs 5                    | 0.45    |
Table 4C: Number of Participants with clinical recovery by Day 7 to 10 post-randomization

| Study           | Country         | Daily dose | Duration   | Endpoint           | Results       | P value |
|-----------------|-----------------|------------|------------|--------------------|---------------|---------|
| Chachar et al   | Pakistan        | 0.2 mg/kg  | 2 days (OL)| Day 7 Clinical     | 64% vs 60%    | p = 0.5 |
| Okumus et al    | Turkey          | 0.2 mg/kg  | 5 days (DB)| Day 10 Clinical    | 73% vs 53%    | p = 0.10|
| Mahmud et al    | Bangladesh      | 12 mg      | 1 day (DB) | Day 7 Clinical     | 61% vs 44%    | p =<0.03|
| Petkov et al    | Bulgaria        | 0.4 mg/kg  | 3 days (DB)| Day 7 Clinical     | 20% vs 14%    | n/a     |
| Elgazzar et al  | Egypt, Mild/Moderate | 0.4 mg/kg | 5 days (OL)| Clinical improvement | 99% vs 74%    | p<0.001 |
| Study          | Country       | Dosage | Duration (Treatment) | Clinical Improvement | Outcome | p-value |
|---------------|---------------|--------|----------------------|----------------------|---------|---------|
| Elgazzar et al | Egypt, n=200  | 0.4 mg/kg | 5 days (OL)          | Clinical improvement | 94% vs 50% | p<0.001 |
| Chahla et al  | Argentina, n=254 | 24 mg | 1/ week for 4 weeks (OL) | Clinical improvement | 98% vs 87% | p=0.0007 |
### Table 5: Effects of ivermectin on survival

| Trial            | Country     | Dosing                  | Ivermectin | Control |
|------------------|-------------|-------------------------|------------|---------|
| Mahmud et al     | Bangladesh  | 0.2 mg/kg, 1 day        | 0/183      | 3/180   |
| Niaee et al      | Iran        | 0.2 mg/kg 1-3 days      | 4/120      | 11/60   |
| Hashim et al     | Iraq        | 0.2-0.4 mg/kg 2-3 days  | 2/70       | 6/70    |
| Elgazzar et al   | Egypt       | 0.4 mg/kg 5 days        | 2/200      | 24/200  |
| Okumus et al     | Turkey      | 0.2 mg/kg, 5 days       | 6/30       | 9/30    |
| Kirti et al      | India       | 12 mg, 5 days           | 0/55       | 4/57    |
| Rezai et al      | Iran        | 0.2 mg/kg, 1 day        | 1/35       | 0/34    |
| Abd-Elsalam      | Egypt       | 0.2 mg/kg, 3 days       | 3/82       | 4/82    |
| Gonzalez         | Mexico      | 0.2 mg/kg, 1 day        | 5/36       | 6/37    |
| Study         | Country   | Treatment   | Cases  | Controls  | Total   |
|--------------|-----------|-------------|--------|-----------|---------|
| Lopez-Medina | Colombia  | 0.3 mg/kg 5 days | 0/200  | 1/198     |         |
| Fonseca      | Brazil    | 14mg 3 days  | 12/53  | 25/115    |         |
| **Total**    |           |             |        |           | 35/1064 (3%) 93/1063 (8.7%) |
### 5.2.1 Single-day dosing

| Study or Subgroup          | Ivermectin | Control | Mean Difference | Mean Difference |
|----------------------------|------------|---------|----------------|----------------|----------------|
|                            | Mean       | SD      | Total | Mean       | SD      | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Ahmed et al IVM+Doxy       | 11.5       | 4.2     | 24    | 12.7       | 3.6     | 24    | 12.2%   | -1.20 [-3.41, 1.01] |
| Bangladesh Chowdhury et al | 9.1        | 1.5     | 60    | 9.7        | 2.2     | 56    | 14.2%   | -0.70 [-1.39, -0.01] |
| Subtotal (95% CI)          |            |         | 84    |            | 80      | 26.4% | -0.74 [-1.40, -0.09] |

Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 2.21 (P = 0.03)

### 5.2.2 Multi-day dosing

| Study or Subgroup          | Ivermectin | Control | Mean Difference | Mean Difference |
|----------------------------|------------|---------|----------------|----------------|----------------|
|                            | Mean       | SD      | Total | Mean       | SD      | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Ahmed et al IVM 5days      | 9.7        | 5       | 24    | 12.7       | 3.6     | 24    | 11.8%   | -3.00 [-5.46, -0.54] |
| Babalola et al 12mg        | 4.7        | 3.2     | 20    | 9.2        | 7.4     | 20    | 9.8%    | -4.50 [-8.03, -0.97] |
| Babalola et al 6mg         | 6          | 3       | 20    | 9.2        | 7.4     | 20    | 9.9%    | -3.20 [-6.70, 0.30]  |
| Bulgaria Petkov et al      | 4.5        | 2.8     | 50    | 5.1        | 2.9     | 50    | 13.8%   | -0.60 [-1.72, 0.52]  |
| Egypt Elgazzar Moderate    | 5          | 1       | 100   | 10         | 4       | 100   | 14.1%   | -5.00 [-5.81, -4.19] |
| Egypt Elgazzar Severe      | 6          | 1       | 100   | 12         | 4       | 100   | 14.1%   | -6.00 [-6.81, -5.19] |
| Subtotal (95% CI)          |            |         | 314   |            | 314     | 73.6% | -3.74 [-5.77, -1.72] |

Heterogeneity: Tau² = 5.22; Chi² = 63.30, df = 5 (P < 0.00001); I² = 92%
Test for overall effect: Z = 3.62 (P = 0.0003)

Total (95% CI) 398 394 100.0% -3.00 [-4.96, -1.03]

Heterogeneity: Tau² = 6.94; Chi² = 139.86, df = 7 (P < 0.00001); I² = 95%
Test for overall effect: Z = 2.99 (P = 0.003)
Test for subgroup differences: Chi² = 7.61, df = 1 (P = 0.006), I² = 86.9%
### 3.7.1 Single-day dosing

| Study or Subgroup          | Ivermectin Events | Control Events | Total | Weight | Risk Ratio IV, Random, 95% CI |
|----------------------------|-------------------|----------------|-------|--------|------------------------------|
| Ahmed et al IVM+Doxy       | 7                 | 24             | 3     | 42     | 2.33 [0.68, 7.97]            |
| India Mohan et al 0.2mg/kg | 13                | 36             | 16    | 42     | 0.95 [0.53, 1.69]            |
| India Mohan et al 0.4mg/kg | 16                | 36             | 16    | 42     | 1.17 [0.69, 1.98]            |
| Pakistan Asghar et al      | 37                | 41             | 20    | 45     | 2.03 [1.44, 2.86]            |
| **Subtotal (95% CI)**      | **137**           | **153**        | **153** | **44.9%** | **1.45 [0.95, 2.23]**      |

Total events: 73, 55

Heterogeneity: Tau^2 = 0.10; Chi^2 = 6.67, df = 3 (P = 0.08); I^2 = 55%

Test for overall effect: Z = 1.71 (P = 0.09)

### 3.7.2 Multi-day dosing

| Study or Subgroup          | Ivermectin Events | Control Events | Total | Weight | Risk Ratio IV, Random, 95% CI |
|----------------------------|-------------------|----------------|-------|--------|------------------------------|
| Ahmed et al IVM 5 days     | 11                | 24             | 3     | 24     | 4.2% 3.67 [1.17, 11.52]      |
| Bulgaria Petkov et al      | 40                | 50             | 37    | 50     | 22.1% 1.08 [0.87, 1.34]      |
| India Kirti et al          | 13                | 32             | 18    | 44     | 11.8% 0.99 [0.57, 1.72]      |
| Israel Schwartz et al      | 33                | 49             | 21    | 45     | 17.0% 1.44 [1.00, 2.09]      |
| **Subtotal (95% CI)**      | **155**           | **163**        | **163** | **55.1%** | **1.26 [0.92, 1.71]**      |

Total events: 97, 79

Heterogeneity: Tau^2 = 0.05; Chi^2 = 5.93, df = 3 (P = 0.11); I^2 = 49%

Test for overall effect: Z = 1.45 (P = 0.15)

**Total (95% CI)**

| Total | 292 | 316 | 100.0% | 1.35 [1.05, 1.75] |

Total events: 170, 134

Heterogeneity: Tau^2 = 0.06; Chi^2 = 15.90, df = 7 (P = 0.03); I^2 = 56%

Test for overall effect: Z = 2.33 (P = 0.02)

Test for subgroup differences: Chi^2 = 0.29, df = 1 (P = 0.59), I^2 = 0%
Figure 1C

| Study or Subgroup          | Ivermectin Mean Difference | Ivermectin SE | Control Total | Control Total Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|----------------------------|----------------------------|----------------|---------------|----------------------|------------------------------------|------------------------------------|
| 2.4.1 Single-day dosing    |                            |                |               |                      |                                    |                                    |
| Bangladesh Chowdhury et al | -1                         | 0.31           | 60            | 56                   | 17.5%                             | -1.00 [-1.61, -0.39]                 |
| Bangladesh Poddar et al    | -1                         | 0.88           | 30            | 32                   | 13.4%                             | -1.00 [-2.72, 0.72]                  |
| India Mohan et al 0.2mg/kg | 0.2                        | 0.58           | 40            | 45                   | 15.8%                             | 0.20 [-0.94, 1.34]                   |
| India Mohan et al 0.4mg/kg | -0.3                       | 0.61           | 40            | 45                   | 15.6%                             | -0.30 [-1.50, 0.90]                  |
| Iran Rezai et al           | -1.1                       | 0.44           | 35            | 34                   | 16.8%                             | -1.10 [-1.96, -0.24]                 |
| Subtotal (95% CI)          |                            |                | 205           | 212                  | 79.0%                             | -0.75 [-1.21, -0.30]                 |

Heterogeneity: Tau² = 0.04; Chi² = 4.57, df = 4 (P = 0.33); I² = 12%
Test for overall effect: Z = 3.22 (P = 0.001)

2.4.2 Multi-day dosing

| Study or Subgroup          | Ivermectin Mean Difference | Ivermectin SE | Control Total | Control Total Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|----------------------------|----------------------------|----------------|---------------|----------------------|------------------------------------|------------------------------------|
| Colombia Lopez-Medina et al| -2                         | 1.53           | 200           | 198                  | 8.7%                              | -2.00 [-5.00, 1.00]                 |
| Iraq Hashim et al          | -7.3                       | 1.03           | 70            | 70                   | 12.2%                             | -7.30 [-9.32, -5.28]                |
| Subtotal (95% CI)          |                            |                | 270           | 268                  | 21.0%                             | -4.77 [-9.96, 0.42]                 |

Heterogeneity: Tau² = 12.34; Chi² = 8.26, df = 1 (P = 0.004); I² = 88%
Test for overall effect: Z = 1.80 (P = 0.07)

Total (95% CI)

| Study or Subgroup          | Ivermectin Mean Difference | Ivermectin SE | Control Total | Control Total Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|----------------------------|----------------------------|----------------|---------------|----------------------|------------------------------------|------------------------------------|
| Total                      |                            |                | 475           | 480                  | 100.0%                             | -1.58 [-2.80, -0.35]                |

Heterogeneity: Tau² = 2.14; Chi² = 43.40, df = 6 (P < 0.00001); I² = 86%
Test for overall effect: Z = 2.52 (P = 0.01)
Test for subgroup differences: Chi² = 2.28, df = 1 (P = 0.13), I² = 56.2%
### Figure 1D

#### 2.1.1 Multi-day Dosing

| Study or Subgroup                      | Experimental Events | Control Events | Total | Weight | Risk Ratio IV, Random, 95% CI |
|----------------------------------------|---------------------|----------------|-------|--------|-------------------------------|
| Argentina Chahla et al                 | 108                 | 110            | 124   | 144    | 1.14 [1.06, 1.22]             |
| Bangladesh Chachar et al               | 16                  | 25             | 15    | 25     | 1.07 [0.69, 1.65]             |
| Bulgaria Petkov et al                  | 10                  | 50             | 7     | 50     | 1.43 [0.59, 3.45]             |
| Colombia Lopez-Medina et al           | 164                 | 200            | 156   | 198    | 1.04 [0.94, 1.15]             |
| Egypt Elgazzar Moderate                | 99                  | 100            | 74    | 100    | 1.34 [1.19, 1.51]             |
| Egypt Elgazzar Severe                  | 94                  | 100            | 50    | 100    | 1.88 [1.54, 2.30]             |
| Turkey Okumus et al                    | 22                  | 30             | 16    | 30     | 1.38 [0.92, 2.05]             |
| **Subtotal (95% CI)**                  | 615                 | 647            |       | 85.9%  | 1.28 [1.10, 1.48]             |

Total events 513 442
Heterogeneity: Tau² = 0.03; Chi² = 33.03, df = 6 (P < 0.0001); I² = 82%
Test for overall effect: Z = 3.17 (P = 0.002)

#### 2.1.2 Single-day dosing

| Study or Subgroup                      | Experimental Events | Control Events | Total | Weight | Risk Ratio IV, Random, 95% CI |
|----------------------------------------|---------------------|----------------|-------|--------|-------------------------------|
| Bangladesh Mahmud et al                | 111                 | 183            | 80    | 180    | 1.36 [1.12, 1.67]             |
| **Subtotal (95% CI)**                  | 183                 | 180            |       | 14.1%  | 1.36 [1.12, 1.67]             |

Total events 111 80
Heterogeneity: Not applicable
Test for overall effect: Z = 3.04 (P = 0.002)

Total (95% CI) 798 827 100.0% 1.29 [1.12, 1.47]
Total events 624 522
Heterogeneity: Tau² = 0.02; Chi² = 34.88, df = 7 (P < 0.0001); I² = 80%
Test for overall effect: Z = 3.65 (P = 0.0003)
Test for subgroup differences: Chi² = 0.27, df = 1 (P = 0.60), I² = 0%
### Figure 1E

#### 6.2.1 Multi-day dosing

| Study or Subgroup          | Ivermectin | Control | Mean Difference | Mean Difference |
|----------------------------|-------------|---------|----------------|----------------|
|                            | IV, Random, 95% CI | IV, Random, 95% CI |
| Ahmed et al IVM 5days      | 9.6 ± 5      | 9.7 ± 4 | -0.10 [-2.66, 2.46] |
| Egypt Abd-Elsalam et al    | 8.8 ± 4.9    | 10.97 ± 5.2 | -2.17 [-3.72, -0.62] |
| Egypt Elgazzar Moderate    | 5 ± 1        | 15 ± 8  | -10.00 [-11.58, -8.42] |
| Egypt Elgazzar Severe      | 6 ± 1        | 18 ± 8  | -12.00 [-13.58, -10.42] |
| **Subtotal (95% CI)**      | 306 ± 50     | 306 ± 50 | -6.12 [-11.57, -0.67] |

Heterogeneity: $\tau^2 = 30.04$; $\chi^2 = 117.60$, df = 3 ($P < 0.00001$); $I^2 = 97$

Test for overall effect: $Z = 2.20$ ($P = 0.03$)

#### 6.2.2 Single-day dosing

| Study or Subgroup          | Ivermectin | Control | Mean Difference | Mean Difference |
|----------------------------|-------------|---------|----------------|----------------|
|                            | IV, Random, 95% CI | IV, Random, 95% CI |
| Ahmed et al IVM + Doxy     | 10.1 ± 4     | 9.7 ± 4 | 0.40 [-1.86, 2.66] |
| Iran Rezai et al           | 6.9 ± 3.1    | 8.4 ± 3.3 | -1.50 [-3.01, 0.01] |
| **Subtotal (95% CI)**      | 58 ± 15      | 59 ± 15 | -0.74 [-2.57, 1.08] |

Heterogeneity: $\tau^2 = 0.84$; $\chi^2 = 1.87$, df = 1 ($P = 0.17$); $I^2 = 47$

Test for overall effect: $Z = 0.80$ ($P = 0.42$)

**Total (95% CI)**

| Ivermectin | Control | Mean Difference | Mean Difference |
|-------------|---------|----------------|----------------|
| 364 ± 50    | 365 ± 50 | -4.27 [-8.60, 0.06] |

Heterogeneity: $\tau^2 = 28.42$; $\chi^2 = 183.11$, df = 5 ($P < 0.00001$); $I^2 = 97$

Test for overall effect: $Z = 1.93$ ($P = 0.05$)

Test for subgroup differences: $\chi^2 = 3.36$, df = 1 ($P = 0.07$), $I^2 = 70.2$
### Figure 1F

| Study or Subgroup       | Ivermectin | Control | Risk Ratio | Risk Ratio |
|-------------------------|------------|---------|------------|------------|
|                         | Events     | Total   | Events     | Total      | IV, Random, 95% CI | IV, Random, 95% CI |
| Bangladesh Chowdhury et al | 0          | 60      | 2          | 56         | 0.19 [0.01, 3.81]  |
| Colombia Lopez-Medina et al | 4          | 200     | 6          | 198        | 0.66 [0.19, 2.30]  |
| Israel Schwartz et al    | 0          | 49      | 3          | 45         | 0.13 [0.01, 2.48]  |
| Lebanon Raad et al       | 0          | 50      | 3          | 50         | 0.14 [0.01, 2.70]  |
| **Total (95% CI)**       |            | **359** |            | **349**    | **0.40 [0.14, 1.08]** |
| Total events             | 4          | 14      |            |            |                      |

Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 1.88$, df = 3 ($P = 0.60$); $I^2 = 0$

Test for overall effect: $Z = 1.80$ ($P = 0.07$)
### Figure 1G

#### 4.3.1 Severe

| Study or Subgroup               | Ivermectin | Control | Risk Ratio | Risk Ratio |
|---------------------------------|------------|---------|------------|------------|
|                                 | Events     | Total   | Events     | Total       | IV, Random, 95% CI | IV, Random, 95% CI |
| Brazil Fonseca et al            | 12         | 53      | 25         | 115        | 18.4%            | 1.04 [0.57, 1.91] |
| Egypt Elgazzar Severe           | 2          | 100     | 20         | 100        | 9.4%             | 0.10 [0.02, 0.42] |
| Mexico Gonzalez et al           | 5          | 36      | 6          | 37         | 12.5%            | 0.86 [0.29, 2.56] |
| Turkey Okumus et al             | 6          | 30      | 9          | 30         | 14.7%            | 0.67 [0.27, 1.64] |
| **Subtotal (95% CI)**           | **219**    | **282** | **55.0%**  |             |                   |                   |

Total events 25
Heterogeneity: Tau² = 0.45; Chi² = 8.90, df = 3 (P = 0.03); I² = 66%
Test for overall effect: Z = 1.30 (P = 0.19)

#### 4.3.2 Mild/moderate

| Study or Subgroup               | Ivermectin | Control | Risk Ratio | Risk Ratio |
|---------------------------------|------------|---------|------------|------------|
|                                 | Events     | Total   | Events     | Total       | IV, Random, 95% CI | IV, Random, 95% CI |
| Bangladesh Mahmud et al         | 0          | 183     | 3          | 180        | 3.2%             | 0.14 [0.01, 2.70] |
| Colombia Lopez–Medina et al     | 0          | 200     | 1          | 198        | 2.8%             | 0.33 [0.01, 8.05] |
| Egypt Abd–Elsalam et al         | 3          | 82      | 4          | 82         | 9.1%             | 0.75 [0.17, 3.25] |
| Egypt Elgazzar Moderate         | 0          | 100     | 4          | 100        | 3.2%             | 0.11 [0.01, 2.04] |
| India Kirti et al               | 0          | 55      | 4          | 57         | 3.3%             | 0.12 [0.01, 2.09] |
| Iran Niaae et al                | 4          | 120     | 11         | 60         | 12.4%            | 0.18 [0.06, 0.55] |
| Iran Rezaei et al               | 1          | 35      | 0          | 34         | 2.8%             | 2.92 [0.12, 69.20] |
| Iraq Hashim et al               | 2          | 70      | 6          | 70         | 8.4%             | 0.33 [0.07, 1.60] |
| **Subtotal (95% CI)**           | **845**    | **781** | **45.0%**  |             |                   |                   |

Total events 10
Heterogeneity: Tau² = 0.00; Chi² = 5.42, df = 7 (P = 0.61); I² = 0%
Test for overall effect: Z = 3.57 (P = 0.0004)

**Total (95% CI)** 1064 1063 100.0% 0.44 [0.25, 0.77]
Total events 35
Heterogeneity: Tau² = 0.35; Chi² = 19.24, df = 11 (P = 0.06); I² = 43%
Test for overall effect: Z = 2.85 (P = 0.004)
Test for subgroup differences: Chi² = 1.54, df = 1 (P = 0.21), I² = 35.1%

![Favours Ivermectin vs Control](https://academic.oup.com/ofid/advance-article-doi/10.1093/ofid/ofab358/6316214)
| Study or Subgroup      | Ivermectin | Control | Risk Ratio           | Risk Ratio           |
|------------------------|------------|---------|----------------------|----------------------|
|                        | Events     | Total   | Events               | Total               |
| Argentina Krolewiecki et al | 1          | 30      | 0                    | 15                   |
| Brazil Fonseca et al    | 12         | 53      | 24                   | 115                  |
| Egypt Abd-Elsalam et al | 3          | 82      | 3                    | 82                   |
| India Kirti et al       | 1          | 55      | 5                    | 57                   |
| India Mohan et al       | 0          | 100     | 0                    | 52                   |
| **Total (95% CI)**      | **320**    | **321** | **100.0%**           | **97 [0.57, 1.67]**  |

Total events: 17, 32

Heterogeneity: $\text{Tau}^2 = 0.00$; $\text{Chi}^2 = 2.26$, df = 3 ($P = 0.52$); $I^2 = 0$

Test for overall effect: $Z = 0.10$ ($P = 0.92$)